DP
Diadema Partners Portfolio holdings
AUM
$161M
This Quarter Return
+0.4%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$161M
AUM Growth
+$161M
(+29%)
Cap. Flow
+$39.8M
Cap. Flow
% of AUM
24.76%
Top 10 Holdings %
Top 10 Hldgs %
70.2%
Holding
94
New
17
Increased
16
Reduced
11
Closed
14
Top Buys
| 1 |
Soleno Therapeutics
SLNO
|
$16M |
| 2 |
Amgen
AMGN
|
$14.5M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$7.7M |
| 4 |
TG Therapeutics
TGTX
|
$5.89M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$4.45M |
Top Sells
| 1 |
Regeneron Pharmaceuticals
REGN
|
$12.7M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$3.54M |
| 3 |
Eli Lilly
LLY
|
$3.5M |
| 4 |
argenx
ARGX
|
$3.48M |
| 5 |
Rhythm Pharmaceuticals
RYTM
|
$2.65M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Soleno Therapeutics
SLNO
$3.6B
| $23.8M | 7.25% | 284,152 +191,150 | +206% | +$16M |
|
|
2
Amgen
AMGN
$155B
| $14.5M | 4.43% | +52,100 | New | +$14.5M |
|
|
3
TG Therapeutics
TGTX
$4.65B
| $13.4M | 4.07% | 371,448 +163,565 | +79% | +$5.89M |
|
4
Neurocrine Biosciences
NBIX
$13.8B
| $11.8M | 3.6% | 94,042 +31,795 | +51% | +$4M |
|
|
5
Eli Lilly
LLY
$657B
| $11.5M | 3.52% | 14,816 -4,486 | -23% | -$3.5M |
|
6
Jazz Pharmaceuticals
JAZZ
$7.75B
| $11.1M | 3.38% | 104,473 +17,284 | +20% | +$1.83M |
|
|
7
BioMarin Pharmaceuticals
BMRN
$11.2B
| $10.6M | 3.23% | 192,877 +140,000 | +265% | +$7.7M |
|
8
Vaxcyte
PCVX
$4B
| $6.45M | 1.96% | 198,285 +105,900 | +115% | +$3.44M |
|
9
Viking Therapeutics
VKTX
$3.04B
| $5.23M | 1.59% | 197,468 +93,347 | +90% | +$2.47M |
|
|
10
Vertex Pharmaceuticals
VRTX
$100B
| $4.45M | 1.36% | +10,000 | New | +$4.45M |
|
11
Protagonist Therapeutics
PTGX
$3.67B
| $4.21M | 1.28% | +76,185 | New | +$4.21M |
|
12
Gilead Sciences
GILD
$140B
| $3.33M | 1.01% | +30,000 | New | +$3.33M |
|
|
13
argenx
ARGX
$43.6B
| $3.29M | 1% | 5,974 -6,305 | -51% | -$3.48M |
|
14
Immunocore
IMCR
$1.62B
| $3.28M | 1% | 104,384 +7,400 | +8% | +$232K |
|
|
15
Regeneron Pharmaceuticals
REGN
$61.5B
| $2.94M | 0.9% | 5,607 -24,221 | -81% | -$12.7M |
|
16
Revolution Medicines
RVMD
$7.1B
| $2.91M | 0.89% | +79,079 | New | +$2.91M |
|
17
Cogent Biosciences
COGT
$1.69B
| $2.82M | 0.86% | 392,213 | – | – |
|
18
Scholar Rock
SRRK
$3.14B
| $2.23M | 0.68% | 62,926 +5,003 | +9% | +$177K |
|
19
iTeos Therapeutics
ITOS
| $2.06M | 0.63% | +206,200 | New | +$2.06M |
|
20
UroGen Pharma
URGN
$900M
| $2.06M | 0.63% | 150,000 +73,780 | +97% | +$1.01M |
|
21
Ultragenyx Pharmaceutical
RARE
$2.89B
| $1.96M | 0.6% | +53,985 | New | +$1.96M |
|
22
Viridian Therapeutics
VRDN
$1.5B
| $1.71M | 0.52% | 122,061 -40,002 | -25% | -$559K |
|
23
Merck
MRK
$210B
| $1.58M | 0.48% | +20,000 | New | +$1.58M |
|
24
Pacira BioSciences
PCRX
$1.2B
| $1.41M | 0.43% | 58,926 +20,000 | +51% | +$478K |
|
25
Olema Pharmaceuticals
OLMA
$375M
| $1.08M | 0.33% | 253,657 +153,657 | +154% | +$655K |
|